Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Aurora Kinase

Aurora kinases are serine/threonine kinases that are essential for cell proliferation. They are phosphotransferase enzymes that help the dividing cell dispense its genetic materials to its daughter cells. More specifically, Aurora kinases play a crucial role in cellular division by controlling chromatid segregation. Defects in this segregation can cause genetic instability, a condition which is highly associated with tumorigenesis.

  • TAK-901
    T2709934541-31-8
    TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others.
    • $66
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • MBM-55S
    T119612083624-07-9In house
    MBM-55S is an effective inhibitor of Nek2 with an IC50 of 1 nM. MBM-55S indecus cell cycle arrest and apoptosis thereby inhibiting the proliferation of cancer cells. MBM-55S shows antitumor activities.
    • $195
    In Stock
    Size
    QTY
  • XU1
    T2917053439-81-9In house
    XU1(Benzo[c][1,8]naphthyridin-6(5h)-One) is an Aurora protein kinase inhibitor used for the treatment of diseases suitable for inhibition, regulation or modulation of kinase signaling.
    • $328
    In Stock
    Size
    QTY
  • SP-146
    T8685
    SP-146 is a selective, potent and non-ATP-competitive Aurora B inhibitor(IC50 : 0.316 nM).
    • $133
    In Stock
    Size
    QTY
  • Ceftriaxone Sodium
    T66175958633-51-7
    Ceftriaxone Sodium is a broad-spectrum β-lactam tertiary cephalosporin antibiotic with anti-inflammatory, antitumor, antibacterial, and antioxidant activities.Ceftriaxone Sodium is a covalent GSK3β and Aurora B inhibitor used in the study of sepsis and infective endocarditis.
    • $39
    Backorder
    Size
    QTY
    TargetMol | Citations Cited
  • LY3295668
    T158151919888-06-4In house
    LY3295668 (AK-01) is a selective inhibitor of Aurora A with Kis of 0.8 nM and 1038 nM for Aurora A and B, respectively.
    • $145
    In Stock
    Size
    QTY
  • Centrinone-B
    T149261798871-31-4In house
    Centrinone-B (LCR-323) is a potent and highly selective inhibitor of PLK4 (Ki: 0.59 nM).
    • $689
    Backorder
    Size
    QTY
  • TCS7010
    T67671158838-45-9
    TCS7010 (Aurora A Inhibitor I) is a novel, potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay. It is 1000-fold more selective for Aurora A than Aurora B.
    • $30
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • SP600125
    T3109129-56-6
    SP600125 (JNK Inhibitor II) is a JNK inhibitor that inhibits JNK1, JNK2, and JNK3 (IC50=40/40/90 nM) with oral potency, reversibility, and ATP-competitive properties. SP600125 inhibits autophagy and induces apoptosis.
    • $41
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Barasertib-HQPA
    T2602722544-51-6
    Barasertib-HQPA (AZD2811) is a highly selective Aurora B inhibitor (IC50: 0.37 nM) and demonstrates ~3,700-fold greater selectivity than Aurora A.
    • $43
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Danusertib
    T2094827318-97-8
    Danusertib (PHA-739358) is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may result in cell growth arrest and apoptosis in tumor cells in which Aurora kinases are overexpressed.
    • $54
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Alisertib
    T22411028486-01-2
    Alisertib (MLN 8237) is a specific Aurora A inhibitor (IC50: 1.2 nM). The selectivity of Alisertib(MLN 8237) is >200-fold higher for Aurora A than Aurora B.
    • $50
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Palmatine
    T5S08023486-67-7
    1. Palmatine (Burasaine) is an inhibitor of dopamine generation. 2. Palmatine could potentially be developed for the treatment of flavivirus infections. 3. Palmatine has been used in the treatment of jaundice, dysentery, hypertension, inflammation, and liver-related diseases.
    • $55
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • AT9283
    T3068896466-04-9
    AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).
    • $39
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Tozasertib
    T2509639089-54-6
    Tozasertib (MK-0457) is a pan-Aurora kinase inhibitor (Kis: 0.6/18/4.6 nM for Aurora A/Aurora B/Aurora C). It shows selectivity against more than 190 different kinases.
    • $62
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • MLN8054
    T6315869363-13-3
    MLN8054 is a potent and selective Aurora A kinase inhibitor with an IC50 of 4 nM.
    • $48
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • SC-514
    T2118354812-17-2
    SC-514 (GK 01140) is a selective, orally active, ATP-competitive IKK-2 inhibitor (IC50=11.2±4.7 μM), obstructs NF-κB-dependent gene expression.
    • $30
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Reversine
    T1825656820-32-5
    Reversine, a small synthetic purine analogue (2, 6-disubstituted purine), is a potent inhibitior of Aurora A/B/C(IC50s=150-500 nM).
    • $32
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Hesperadin
    T6532422513-13-1
    Hesperadin(IC50=250 nM) effectively inhibits Aurora B. It potently reduces the activity of AMPK, MAPKAP-K1, MKK1, Lck, CHK1 and PHK, but it could not inhibit MKK1 activity in vivo.
    • $33
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • TAK-632
    T18861228591-30-7
    TAK-632 is a potent pan-Raf inhibitor.
    • $35
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Aurora A inhibitor 3
    T82931
    Aurora A Inhibitor 3 (Compound 5h) effectively inhibits Aurora-A kinase, exhibiting an IC50 of 0.78 μM, and demonstrates cytotoxicity against MCF-7 and MDA-MB-231 cell lines with GI50 values of 0.12 μM and 0.63 μM, respectively [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • 11α-O-Tigloyl-12β-O-acetyltenacigenin B
    T83459154022-51-2
    11α-O-Tigloyl-12β-O-acetyltenacigenin B, an ester derivative isolated from Garcinia cambogia (MTC), modulates the antitumor effects of Aurora-A in lymphoma through its parent compound, Tenacigenin B.
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • AKI603
    T643381432515-73-5
    AKI603 is a novel small molecule inhibitor of Aurora kinase A (AurA)(IC50 = 12.3 nM). AKI603 is developed to overcome resistance mediated by BCR-ABL-T315I mutation. AKI603 exhibits strong anti-proliferative activity in leukemic cells[1][2].
    • $116
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • CCT241736
    T44281402709-93-6
    CCT241736 is an orally bioavailable dual FLT3/Aurora kinase inhibitor that also inhibits clinically relevant FLT3-resistant mutants including FLT3-ITD and FLT3, CCT241736, an advanced analog of CCT137690, is a preclinical development candidate for the treatment of human malignancies, and in particular AML in adults and children.
    • $55
    In Stock
    Size
    QTY
  • SNS-314 Mesylate
    T26171146618-41-8
    SNS-314 Mesylate (SNS-314) is an effective and specific Aurora A/B/C inhibitor (IC50: 9/31/3 nM). It is less inhibition of Trk A/B, Fms, Flt4, c-Raf, Axl, and DDR2.
    • $39
    In Stock
    Size
    QTY
  • Ilorasertib
    TQ00591227939-82-3
    Ilorasertib (ABT-348) (ABT-348) is an ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora A/Aurora B/Aurora C (IC50s: 120 nM/7 nM/1 nM). It also suppresses RET tyrosine kinase, PDGFRβ, and Flt1 (IC50s: 7 nM, 3 nM, and 32 nM).
    • $55
    In Stock
    Size
    QTY
  • MK-5108
    T60681010085-13-8
    MK-5108 (VX-689) is a highly potent and specific Aurora-A kinase inhibitor with an IC50 value of 0.064 nM.
    • $34
    In Stock
    Size
    QTY
  • PHA-680632
    T6338398493-79-3
    PHA-680632 is potent inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 27 nM, 135 nM and 120 nM, respectively. It has 10- to 200-fold higher IC50 for FGFR1, FLT3, LCK, PLK1, STLK2, and VEGFR2/3.
    • $39
    In Stock
    Size
    QTY
  • L 888607 Racemate
    T158291030017-51-6
    L 888607 Racemate is a selective antagonist of prostaglandin D2 receptor subtype 1 (DP1) (Kis: 132 nM and 17 nM for DP1 and thromboxane A2 receptor (TP), respectively).
    • $1,080
    Backorder
    Size
    QTY
  • NU6140
    T16359444723-13-1
    NU6140 is a selective inhibitor of CDK2-cyclin A (IC50, 0.41 μM). It shows 10- to 36-fold selectivity over other CDKs. NU6140 also effectively inhibits Aurora A and Aurora B (IC50s: 67 and 35 nM, respectively). It also enhances the apoptotic effect and has anti-cancer activity.
    • $41
    In Stock
    Size
    QTY
  • MBM-17S
    T119592083621-91-2
    MBM-17S, a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC50 of 3 nM, effectively inhibits cancer cell proliferation by inducing cell cycle arrest and apoptosis. It demonstrates antitumor activities without evident toxicity to mice.
    • $1,670
    Backorder
    Size
    QTY
  • Centrinone
    T149271798871-30-3
    Centrinone (LCR-263) (LCR-263) is a reversible inhibitor of polo-like kinase 4 (PLK4; Ki:0.16 nM).
    • $56
    In Stock
    Size
    QTY
  • Tripolin A
    T85371148118-92-6
    Tripolin A is a specific non-ATP competitive inhibitor of Aurora A kinase(Aurora A and Aurora B with IC50 values of 1.5 μM and 7 μM, respectively)
    • $817
    Backorder
    Size
    QTY
  • Phthalazinone pyrazole
    T21981880487-62-7
    Phthalazinone pyrazole is potent, selective, and orally bioavailable inhibitor of Aurora-A kinase. Aurora-A is overexpressed in a variety of tumor types and displays oncogenic activity.
    • $116
    In Stock
    Size
    QTY
  • GW843682X
    T15454660868-91-7
    GW843682X (GW843682) is a selective and ATP-competitive inhibitor of PLK1 and PLK3 (IC50s = 2.2 nM and 9.1 nM).
    • $32
    In Stock
    Size
    QTY
  • CCT 137690
    T26111095382-05-0
    CCT 137690 is a highly specific and oral-available aurora kinase inhibitor, for aurora A(IC50=15 nM ), B(IC50=25 nM) and C(IC50=19 nM).
    • $51
    In Stock
    Size
    QTY
  • ZM-447439
    T6077331771-20-1
    ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.
    • $45
    In Stock
    Size
    QTY
  • CYC-116
    T6458693228-63-6
    CYC116 is a potent inhibitor of Aurora A/B with Ki of 8.0 nM/9.2 nM, is less potent to VEGFR2 (Ki of 44 nM), with 50-fold greater potency than CDKs, not active against PKA, Akt/PKB, PKC, no effect on GSK-3α/β, CK2, Plk1 and SAPK2A. Phase 1.
    • $33
    In Stock
    Size
    QTY
  • Aurora Kinases-IN-4
    T787532877011-84-0
    Aurora Kinases-IN-4 (Compound 11c) is a covalent, ATP-competitive inhibitor of aurora kinase A with an IC50 value of 1.7 nM. It demonstrates cell proliferation inhibition in SJSA-1, MDA-MB-231, A549, and HeLa cell lines with IC50 values of 4.27, 1.54, 3.08, and 6.99 μM, respectively. This compound is applicable in research concerning triple-negative breast cancer (TNBC) [1].
    • $1,670
    Backorder
    Size
    QTY
  • MBM-17
    T119582083621-90-1
    MBM-17 is a potent inhibitor of NIMA-related kinase 2 (Nek2,IC50 of 3 nM). It effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis.
    • $1,670
    Backorder
    Size
    QTY
  • PF-03814735
    T6936942487-16-3
    PF-03814735 is a novel, potent and reversible inhibitor of Aurora A/B with IC50of 0.8 nM/5 nM, is less potent to Flt3, FAK, TrkA, and minimally active to Met and FGFR1. Phase 1.
      7-10 days
      Inquiry
    • dAURK-4 hydrochloride
      T74100
      dAURK-4 hydrochloride is a selective AURKA (Aurora A) degrader with anticancer and antiproliferative activities. dAURK-4 hydrochloride has been shown to be an anticancer and antiproliferative agent.
      • $132
      In Stock
      Size
      QTY
    • Palmatine chloride
      T271810605-02-4
      Palmatine chloride an isoquinoline alkaloid, is an important medicinal herbal extract with diverse pharmacological and biological properties.
      • $39
      In Stock
      Size
      QTY
    • Chiauranib
      T355701256349-48-0
      Chiauranib is a multi-target inhibitor against tumor angiogenesis and exhibits potent anticancer effects. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF1R, with IC50 values ranging from 1-9 nM.
      • $83
      In Stock
      Size
      QTY
    • Aurora kinase inhibitor-2
      T9040331770-21-9
      Aurora kinase inhibitor-2 (IUN-70219) is a cell-permeable anilinoquinazoline that inhibit the activity of Aurora A (IC50 = 0.39 M).
      • $127
      In Stock
      Size
      QTY
    • SCH-1473759 hydrochloride
      T128641094067-13-6
      SCH-1473759 hydrochloride is an inhibitor of aurora(aurora A and B with IC50s of 4 and 13 nM, respectively).
      • $113
      5 days
      Size
      QTY
    • Ilorasertib hydrochloride
      T116381847485-91-9
      Ilorasertib hydrochloride (ABT-348 hydrochloride) is an ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora C, Aurora B, and Aurora A (IC50s: 1 nM, 7 nM, 120 nM). It also suppresses RET tyrosine kinase, PDGFRβ, and Flt1 (IC50s: 7 nM, 3 nM, and 32 nM).
      • $64
      In Stock
      Size
      QTY
    • TC-A 2317 hydrochloride
      T234261245907-03-2
      TC-A 2317 hydrochloride is an inhibitor of Aurora kinase A with a Ki of 1.2 nM compared to Aurora kinase B with a Ki of 101 nM. TC-A 2317 hydrochloride shows antitumor activity.
      • $3,180
      35 days
      Size
      QTY
    • GW779439X
      T8866551919-98-3
      GW779439X is an inhibitor of CDK.
      • $56
      In Stock
      Size
      QTY
    • AMG 900
      T6380945595-80-2
      AMG 900 is a potent and highly selective pan-Aurora kinases inhibitor for Aurora A/B/C with IC50 of 5 nM/4 nM /1 nM. It is >10-fold selective for Aurora kinases than p38α, Tyk2, JNK2, Met and Tie2. Phase 1.
      • $44
      In Stock
      Size
      QTY